Bacteriophage Therapy Summit

The bacteriophage community is experiencing a period of renaissance of funding and clinical breakthroughs, with 2023 having been a pivotal year when the UK government injected £210m to tackle global antimicrobial resistance. As the only industry-led platform for phage drug developers, the 6th Bacteriophage Therapy Summit will return to Boston in 2024 to unite 90+ phage experts that will:

Expedite Phage Discovery Through High-Throughput Screening and AI to Enhance Targeting and Specificity

Bridge the Gap of Engineered, Natural, and Hybrid Phage to Expand Flexibility

Navigate Regulatory Pathways of Phage to Ensure Successful Clinical Trials

Broaden Phage's Therapeutic and Delivery Vehicle Potential Beyond AMR

URLs:
Website: https://go.evvnt.com/2101978-0?pid=10018
Tickets: https://go.evvnt.com/2101978-2?pid=10018
Brochure: https://go.evvnt.com/2101978-3?pid=10018

Prices:
Drug Developer - Conference Only: USD 2599.00,
Drug Developer - Conference + 1 Workshop: USD 3148.00,
Drug Developer - Conference + 2 Workshops: USD 3697.00,
Service and Solution Provider - Conference Only: USD 3299.00,
Service and Solution Provider - Conference + 1 Workshop: USD 3848.00,
Service and Solution Provider - Conference + 2 Workshops: USD 4397.00

Speakers: Jakob Krause Haaber, Vice President of CRISPR and Delivery Technologies, SNIPR Biome, James Cass, Director of Molecular and Viral Safety, Merck, Jaroslaw Dastych, Chief Executive Officer, Proteon Pharmaceuticals, Jason Clark, Chief Scientific Officer, NexaBiome, Johan Wikstrom, CEO, Tolka AI Therapeutics, Keiko Salazar, Assistant Director, Baylor College of Medicine (TAILOR), Matjaz Peterka, Chief Executive Officer, COBIK, Pablo Cifuentes, Chief Technology Officer, PhageLab, Paul Kim, Chief Development Officer, Locus Biosciences, Sergei Petukhov, Managing Director, AMR Action Fund, Urania Rappo, Director of Clinical Development, BiomX